Breaking News Instant updates and real-time market news.

BMY

Bristol-Myers

$55.43

0.38 (0.69%)

, MRK

Merck

$62.77

0.11 (0.18%)

07:55
10/10/16
10/10
07:55
10/10/16
07:55

Leerink sees Bristol-Myers sliding after Merck's 'spectacular' Keytruda data

Leerink analyst Seamus Fernandez said Bristol-Myers' (BMY) Checkmate-026 data presented at the European Society of Medical Oncology meeting was disappointing, noting there was no signal of benefit on progression-free survival or overall survival and only "modest differentiation" on response rate in the 88 patients with PDL1 biomarker positivity greater than or equal to 50%. Meanwhile, Merck (MRK) presented "spectacular" data for Keytruda monotherapy at the meeting, said Fernandez, who expects Bristol shares to be down "significantly" today in light of the meeting presentations. The analyst, who still thinks Bristol has a significant opportunity to compete with Merck's Keytruda in the PDL1 high portion of the market, keeps an Outperform rating on Bristol shares, which are down nearly 6% in pre-market trading.

BMY

Bristol-Myers

$55.43

0.38 (0.69%)

MRK

Merck

$62.77

0.11 (0.18%)

  • 25

    Oct

  • 27

    Oct

  • 31

    Oct

  • 06

    Nov

BMY Bristol-Myers
$55.43

0.38 (0.69%)

09/28/16
ROTH
09/28/16
NO CHANGE
Target $23
ROTH
Buy
Nektar price target raised to $23 from $19 at Roth Capital
Roth Capital analyst Michael Higgins raised his price target for Nektar (NKTR) to $23 from $19 after the company and Bristol-Myers (BMY) announced a clinical collaboration to evaluate the combination of the latter's anti-PD-1 antibody, Opdivo, with NKTR-214. The analyst reiterates a Buy rating on Nektar's shares.
09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.
09/20/16
SBSH
09/20/16
NO CHANGE
Target $70
SBSH
Buy
Bristol-Myers price target lowered to $70 from $75 at Citi
In a research note titled "Brace Yourself. Attractive Valuation but No Near-Term Respite.," Citi analyst Andrew Baum lowered his price target for shares of Bristol-Myers Squibb to $70 from $75. The analyst lowered his earnings forecasts by up to 8% to reflect the "limited supportive data" in the non-small cell lung cancer indication. Baum keeps a Buy rating on the shares as he views the valuation as attractive. He points out, however, the near-term news-flow is likely to be negative.
09/12/16
JEFF
09/12/16
NO CHANGE
Target $57
JEFF
Hold
Jefferies cuts Bristol-Myers price target, upgrades AstraZeneca
Jefferies analyst Jeffrey Holford lowered his price target for Bristol-Myers Squibb (BMY) to $57 from $69 saying the stock is positioned for a "rough mid term ride." The analyst sees a "difficult catalyst" set for Bristol shares with "numerous" upcoming competitor read-outs in non-small cell lung cancer. The market could see worse than expected data from Bristol's CM-026 and CM-568 studies as well as better than expected data from AstraZeneca's (AZN) MYSTIC study and Roche's (RHHBY) Chemo-IO studies in the first half of 2017, Holford tells investors in a research note. He keeps a Hold rating on Bristol and upgraded this morning AstraZeneca to Buy from Hold. Holford prefers Astra for its immunology exposure.
MRK Merck
$62.77

0.11 (0.18%)

10/07/16
LEER
10/07/16
NO CHANGE
LEER
Outperform
Incyte Epacadostat Phase 1 Melanoma data maturing well, says Leerink
Leerink analyst Michael Schmidt says the data from ECHO-202 Phase 1 study evaluating the combination of Incyte's (INCY) IDO1 inhibitor epacadostat with Merck's (MRK) Keytruda confirms the previously published results and appears to be maturing well. The analyst reiterates an Outperform rating on Incyte's shares, saying Jakafi remains a compelling long-term growth driver for the company, expectations for baricitinib are still moderate, and its maturing oncology pipeline of 14 molecules including epacadostat represents a long-term value driver.
10/03/16
LEER
10/03/16
NO CHANGE
LEER
Market Perform
AASLD abstracts hint at potential competitive threat to Gilead HCV, says Leerink
Leerink analyst Geoffrey Porges says abstracts for the American Association for the Study of Liver Diseases, or AASLD, meeting revealed very limited efficacy information about the new Hepatitis C regimens for Gilead (GILD), Merck (MRK) and AbbVie (ABBV). Nonetheless, the analyst believes the abstracts hint at the potential competitive threat to Gilead's HCV dominance. While the new 12-week HCV regimens may compete on price, the forthcoming 8-week regimens put the most pressure on Gilead's market share, Porges argues. He reiterates a Market Perform rating on Gilead's shares.
09/21/16
FBCO
09/21/16
UPGRADE
Target $41
FBCO
Outperform
Clovis upgraded to Outperform from Neutral at Credit Suisse
Credit Suisse analyst Kennen MacKay upgraded Clovis Oncology (CLVS) to Outperform and raised his price target for the shares to $41 from $19. Clovis closed yesterday up 13%, or $3.92, to $34.83. The potential for a takeover "outweighs concerns surrounding patent life, limited experience in platinum resistant/refractory patients, and PARPi competition," MacKay tells investors in a research note. Clovis could be worth $35-$41 per share in a buyout on operational synergies, and $52-$55 per share with leveraged tax benefits, MacKay estimates. He points out that Eli Lilly (Lill)y, Merck (MRK), Japan's Takeda and others have expressed interest in acquiring U.S. oncology companies.

TODAY'S FREE FLY STORIES

WTI

W&T Offshore

$1.97

0.03 (1.55%)

16:18
12/09/16
12/09
16:18
12/09/16
16:18
Hot Stocks
W&T Offshore CEO acquires over 1.18M common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALNY

Alnylam

$42.25

1.445 (3.54%)

16:16
12/09/16
12/09
16:16
12/09/16
16:16
Hot Stocks
Breaking Hot Stocks news story on Alnylam »

Dodge & Cox reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Dec

$NYE

NYSE Market Internals

16:16
12/09/16
12/09
16:16
12/09/16
16:16
Technical Analysis
NYSE market internals summary »

Breadth is mixed with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVO

Cenveo

$6.84

-0.16 (-2.29%)

16:16
12/09/16
12/09
16:16
12/09/16
16:16
Hot Stocks
Breaking Hot Stocks news story on Cenveo »

Brigade Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

16:16
12/09/16
12/09
16:16
12/09/16
16:16
Technical Analysis
NASDAQ market internals summary »

Volume is very heavy for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLRB

Cellectar Biosciences

$1.33

-0.04 (-2.92%)

16:15
12/09/16
12/09
16:15
12/09/16
16:15
Hot Stocks
Cellectar, INC Research enter into Work Order »

According to a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INSW

International Seaways

$14.40

0.86 (6.35%)

16:12
12/09/16
12/09
16:12
12/09/16
16:12
Hot Stocks
Breaking Hot Stocks news story on International Seaways »

Cyrus Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BFS

Saul Centers

$66.45

-0.96 (-1.42%)

16:09
12/09/16
12/09
16:09
12/09/16
16:09
Hot Stocks
Saul Centers raises quarterly dividend 8.5% to 51c from 47c per share »

The dividend is to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASNA

Ascena Retail

$8.04

-0.07 (-0.86%)

16:08
12/09/16
12/09
16:08
12/09/16
16:08
Hot Stocks
Ascena Retail names David Jaffe chairman of the board »

Ascena Retail announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MORN

Morningstar

16:08
12/09/16
12/09
16:08
12/09/16
16:08
Hot Stocks
Morningstar raises quarterly dividend to 23c from 22c per share »

The dividend is payable…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SAND

Sandstorm Gold

$3.83

-0.19 (-4.73%)

16:07
12/09/16
12/09
16:07
12/09/16
16:07
Syndicate
Breaking Syndicate news story on Sandstorm Gold »

Sandstorm Gold files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACIU

AC Immune

$14.93

2.88 (23.90%)

, RHHBY

Roche

$27.86

0.78 (2.88%)

16:05
12/09/16
12/09
16:05
12/09/16
16:05
Hot Stocks
AC Immune partner Genentech presents 'important' data on Alzheimer's therapy »

AC Immune (ACIU)…

ACIU

AC Immune

$14.93

2.88 (23.90%)

RHHBY

Roche

$27.86

0.78 (2.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDVX

Medovex

$1.50

0.03 (2.04%)

16:03
12/09/16
12/09
16:03
12/09/16
16:03
Hot Stocks
Breaking Hot Stocks news story on Medovex »

Sorrento Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BDC

Belden

$78.79

-1.69 (-2.10%)

16:01
12/09/16
12/09
16:01
12/09/16
16:01
Hot Stocks
Belden extends shareholder rights agreement »

Belden announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GENE

Genetic Technologies

$1.19

-0.01 (-0.83%)

15:59
12/09/16
12/09
15:59
12/09/16
15:59
Hot Stocks
Breaking Hot Stocks news story on Genetic Technologies »

CVI Investments reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FLO

Flowers Foods

$19.26

2.2325 (13.11%)

15:53
12/09/16
12/09
15:53
12/09/16
15:53
Recommendations
Flowers Foods analyst commentary  »

Flowers Foods settlement…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAL

Halliburton

$54.22

-0.21 (-0.39%)

15:50
12/09/16
12/09
15:50
12/09/16
15:50
Options
Halliburton Dec 48.5 puts for a nickel per contract »

Halliburton Dec 48.5 puts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

BIIB

Biogen

$289.54

4.24 (1.49%)

15:43
12/09/16
12/09
15:43
12/09/16
15:43
Recommendations
Biogen analyst commentary  »

Piper says Biogen still…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VLO

Valero

$67.84

-0.535 (-0.78%)

15:40
12/09/16
12/09
15:40
12/09/16
15:40
Options
Higher option volume in Valero driven by downside put purchases »

Higher option volume in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SKLN

Skyline Medical

$2.94

-0.01 (-0.34%)

15:36
12/09/16
12/09
15:36
12/09/16
15:36
Syndicate
Skyline Medical files to sell 1.925M units »

Each unit consisting of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HMNY

Helios and Matheson

$4.26

-0.08 (-1.84%)

15:35
12/09/16
12/09
15:35
12/09/16
15:35
Hot Stocks
Farnsworth acquires 1.74M Helios and Matheson shares as part of merger pact »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FLO

Flowers Foods

$19.10

2.07 (12.16%)

15:32
12/09/16
12/09
15:32
12/09/16
15:32
Upgrade
Flowers Foods rating change  »

Flowers Foods upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WBA

Walgreens Boots Alliance

$84.28

-0.71 (-0.84%)

, RAD

Rite Aid

$8.20

0.045 (0.55%)

15:25
12/09/16
12/09
15:25
12/09/16
15:25
Periodicals
Walgreens near finalizing Rite Aid divestiture package, CTFN reports »

Walgreens (WBA) is…

WBA

Walgreens Boots Alliance

$84.28

-0.71 (-0.84%)

RAD

Rite Aid

$8.20

0.045 (0.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jan

BAS

Basic Energy

$0.44

-0.0039 (-0.89%)

15:19
12/09/16
12/09
15:19
12/09/16
15:19
Hot Stocks
Breaking Hot Stocks news story on Basic Energy »

Basic Energy trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

15:16
12/09/16
12/09
15:16
12/09/16
15:16
Technical Analysis
NYSE market internals summary »

Breadth is mixed with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.